FDA approves first GLP-1 pill for obesity from Novo Nordisk

FDA approves first GLP-1 pill for obesity from Novo Nordisk

Published Mon, Dec 22 2025

6:06 PM EST

Updated 1 Min Ago

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025.

Tom Little | Reuters

The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Novo Nordisk, a landmark decision that health experts say could potentially open up treatment access to more patients.

This is breaking news. Please refresh for updates.

Source